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Abstract
The severe acute respiratory syndrome
corona virus (SARS-CoV)and severe acute
respiratory syndrome corona virus-2 (SARSCoV-2), both virus spike proteins are recognized
by the cell surface receptors, human angiotensin
converting enzyme-2 (ACE-2).These viruses
gain access into the host cell through ACE2receptors.The main aim of the current study
was to elaborate on the structural differences
in the receptor binding domain (RBD) of spike
glycoprotein in SARS-CoV and SARS-CoV-2
that bind at the same active binding site. The
crystal structures of receptor bound spikes of
SARS-CoV and SARS-CoV-2 were compared
using UCSF Chimera and pyMOL software
which revealed significant differences in the
receptor binding domain of the spikes with
variation in the amino acid residues. It was also
observed that conformational changes occurred
in the amino acid residues at the binding site
on ACE-2 receptor. These conformational
changes in ACE-2 binding site of SARSCoV-2 were attributed to a greater number of
contacts forming between RBD and active
binding site when compared to that of SARSCoV and could explain any differences in the
effectiveness of drugs against SARS-CoV and
SARS-CoV-2. In addition, using Autodock vina
software, drugs that were found to be effective
in SARS-COV treatment were docked at
active binding site on ACE-2.Antivirals, ACE2 inhibitors and corticosteroids were docked
at the active binding site domains of ACE2 receptor in SARS-CoV andSARS-CoV-2.
Antivirals such as Oseltamivir, Umifenovir,
Favipiravir, Remdesivir and antibiotics such as

Moxifloxacin and Azithromycin, Ace-2. Antivirals
inhibitors such as Losartan and steroids such as
Dexamethasone have shown a greater negative
docking score (indicating more binding affinity)
in and SARS-CoV-2 when compared to that of
SARS-CoV. This kind of preliminary analysis
using computational techniques could help in
screening and repurposing the existing drugs
that are potential in treating new diseases such
as CoVID-19.
Keywords SARS-CoV-2, ACE-2 receptors,
RBD, Docking, Score.
Introduction
The viral infections continue to emerge and
pose a serious public health issue. The present
pandemic is caused by corona virus belonging
to the genus β corona virus of corona viridae
family. The disease started as an outbreak with
pneumonia like respiratory disease symptoms.
So far there were six corona viruses that
infected humans and the novel corona virus
(Covid-19)was the seventh human corona virus.
Around the world people commonly get infected
by human corona viruses such as 229E, NL63,
HKU1, OC43. These four human corona viruses
cause mild to moderate flu like symptoms (1).
Till date worldwide deaths due to COVID-19
have reached up to 2.1 millionand continue to
increase daily (2).
Corona viruses that infect animals,
sometimes evolve as human corona viruses,
which include severe acute respiratory
syndrome corona virus (SARS-CoV), Middle
east respiratory syndrome (MERS-CoV)and
the present severe acute respiratory syndrome
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corona virus-2 (SARS-CoV-2/Covid-19) making
it the third zoonotic corona virus.Unlike the
other corona viruses these three viral infections
cause severe symptoms ranging from severe
respiratory distress to death.
The SARS-CoV-2 has many similarities
with that of SARS-CoV, as both cause respiratory
illness, spread of disease is by contact and
via the droplets produced by sneezing or
coughing by an infected person, recognized
by angiotensin converting enzyme-2 (ACE2) receptors (3). Both these virus’s genome
consists of an enveloped single stranded
positive RNA (4).Various studies reported that
virus gains access to the host cell is via binding
to cell surface receptors. The SARS-CoV -2 was
known to bind to ACE-2 receptors on the surface
of the respiratory epithelial cells.The structural
analysis of receptor bound SARS-CoV and
SARS-CoV-2 spike proteins revealed the active
binding spots on ACE-2 receptors (5).But the
drugs that were widely used and effective in
treating SARS-CoV such as, Ribavarin, Methyl
prednisolone, levofloxacin were ineffective in
case of SARS-CoV-2.
The present study focuses on the analysis
of differences between the spike proteins of
SARS-CoV and SARS-CoV-2, their binding
sites on human ACE-2 receptors and the
conformational changes at the binding sites.
In addition, various drugs that were effective in
SARS-CoV such as anti virals, ACE-2 inhibitors
and corticosteroids were docked at the spike
receptor binding sites on ACE-2 receptor and
compared the drug binding affinities to address
why the drugs used in treating SARS-CoV failed
to treat COVID-19.
Materials and Methods
To study the structural features and
analyze the binding affinity of drug moieties,
three different software were used– namely,
UCSF Chimera, pyMOL and Autodock vina. The
crystal structures of ACE-2 receptor bound to the
virus spike glycoprotein were obtained from the
protein data bank. SARS-CoV: PDB code=3SCI
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and SARS-CoV-2: PDB code=6VW1.
The 3D structures of drug moieties were
obtained from pubchem data base.The crystal
structures of SARS-CoV and SARS-CoV-2were
overlapped using UCSF Chimera and the
RMSD values were calculated.The interface
interactionsbetween the spike RBD and ACE-2
receptor were analyzed using pyMOL software.
RMSD (Root mean square deviation) is often
used to measure the quality of reproduction of
a known binding pose.A low RMSD with respect
to a true binding pose is good.Ideally less than
1Aº.
RMSD=√((Σ_i d_i^2)/n)
Where, d=distance between each of the
n pairs of equivalent atoms in two optimally
superposed structures.The RMSD value is ‘0’
for identical structures.The values increase
as the two structures become more different.
Docking was performed by Autodock vina and
the resulting files were analyzed tostudy of
type and strength of interactions between drug
molecule and ACE-2 receptor using pyMOL.
The result of docking was obtained as docking
score, which is a mathematical function used
to approximately predict the binding affinity
between two molecules after they have been
docked. This score mimics the potential energy
change when the protein and ligand come
together. The greater the negative score the
stronger is the binding affinity.
Results and Discussion
The first objective of the study was to
examine the crystal structures of SARS-CoV and
SARS-CoV-2spikes bound to ACE-2 receptors
and visualize the structural differences.Majority
of the crystal structure between SAR-CoV
and SARS-CoV-2 spike bound to the ACE2 receptor was be similar, except for the loop
of the spike at the interface (Fig-1A,1B). The
RBDs of spike proteins of SARS-CoV and
SARS-CoV-2 consists of 174 and 194 residues,
respectively.Overlapping the spike RBDs using
UCSF Chimera and an evaluation across all 171
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Fig1. (A). SARS-CoV RBD binding to ACE-2,
(B). SARS-CoV-2 RBD binding to ACE-2and
highlighted area in the box shows the variation
of distance between loop and N-terminal helix of ACE-2. (C). overlap of RBD-SARS-CoV(
green) and SARS-CoV-2 (red), (D). Amino acids
at the loop in purple for SARS-CoV and in blue
for SARS-CoV-2.
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superposed residues showed an overall RMSD
of 2.011 and 63.59 percent identity. There was
a variation at the loop that interacts with ACE2 receptor. The loop in SARS-CoV consists
of proline-proline-alanine, a three amino acid
motif, where the tandem prolines (Fig-1D) take
a sharp turn. In case of SARS-CoV-2 the loop
consists of four amino acids, glycine-valineglutamine-glycine. This extra amino acid in the
loop and the two flexible glycine led to a wider
loop allowing it to form more interactions with
the ACE-2 receptor. In case of all corona virus
RBDs the distance between the two-disulfide
containing cysteine residues was crucial. Due
to these structural differences, extra hydrogen
bonds were formed between the main chain of
ACE-2 and asparagine-487 and alanine-475
of the SARS-CoV-2 RBM.As a result of these
hydrogen bonds with the main chain, the ridge
takes a more compact conformation and the
loop with alanine -475 gets closer to the AEC2. The consequence of this moving of the loop
closer led to a greaternumber of contacts with
the N-terminal helix of ACE-2. As shown in
figure-3, clearly indicated the interactions that
led to a more compact fit on to the binding
site(6).

Fig. 2. Docking of losartan (in blue) at the RBD binding site residues (in grey) of ACE-2 crystalstructure
in (A) SARS-CoV and (B) SARS-CoV-2.
Structural differences between SARS-CoV and SARS-CoV-2
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Fig. 3.The ridge in the SARS-CoV-2 RBD (right)forms more contacts with the N-terminal helix of ACE-2.
The ACE-2 receptor binding domains in
crystal structures of SARS-CoV and SARSCoV-2 were overlapped. An evaluation across
all 588 superposed residues showed an overall
RMSD of 1.382 and a 96.82 percent identity of
the sequences, indicating certain conformational
changes at the binding sites. The ACE-2
receptors have two hotspots for RBD binding.

One hot spot includes tyrosine-41 and the other
lysine-353.All the interactions at the interface of
ACE-2 and the RBD of SARS-CoV and SARSCoV-2 within a range of 3Aº as shown in Table
1. Initially a cutoff distance of 4Aº was selected
which included all polar and π-interactions. To
exclude the weaker interactions amongst these,
a cutoff distance of 3Aº was selected.

Table1. Interface interactions between RBD of spike protein and ACE-2 receptors.
SARS-CoV
ACE-2 Residues

RBD Residues

SARS-CoV-2
Bond
length

ACE-2 Residues

RBD Residues

(Aº)
Glutamine-24

Asparagine
473

2.7

Bond
length
(Aº)

Serine-19
Lysine-31

Aspartic acid -38

Tyrosine -438

2.6

Tyrosine-41
Glutamine-42
Lysine-353

Threonine-486
Tyrosine-484
Threonine-487

2.4
2.9
2.9

Aspartic acid-38
Tyrosine-41
Tyrosine-83

Aspartic acid-355

Thronine-486

3.0

Lysine-353

Glutamic acid-35
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Alanine-475

Glutamine-493

2.6
2.9
2.9

Tyrosine-449
Threonine-500
Asparagine -487

3.0
2.6
2.9

Glycine-496

3.0

Glycine -502

2.8
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Table2. Bond length and interactions between losartan and lysine 353 of ACE-2 receptors.
SARS-CoV

SARS-CoV-2

Number of interactions between losartan and lysine-353
with in 3Aº

3

9

Bond lengths

2.4, 2.6, 2.9

2.2, 2.4, 2.5, 2.8, 2.8, 2.9,2.9,
2.9, 2.9

Table3. List of drugs binding at ACE-2 receptors with their docking score.
Score
SARSCoV-2

Drugs

Effectiveness in Covid-19
Antibiotics

Levofloxacin

-5.2

-5.0

Not effective

Moxifloxacin

-4.6

-5.1

Effective (7).

Hydroxy chloroquine

-4.3

-4.5

Nosignificant outcomes(8, 9, 10).
Corticosteroids

Methyl prednisolone

-6.1

-3.9

Dexamethasone

-6.6

-6.4

prednisone

-5.7

Telmisartan
Enalapril
Losartan
Valsartan

-6.1
-4.9
-4.4
-5.0

Remdesivir

-5.2

oseltamivir

-3.9

Umifenovir

-4.2

Ribavirin
Favipiravir

-5.5
-4.3

Azithromycin

-3.5

Not effective

Treats pneumonia & hyperinflammatory syndrome. (11) Decreased mortality rate by 1/3 in
patients requiring ventilator (12).
Treats pneumonia & hyperinflammatory syn-5.8
drome(13).
ACE-2 inhibitors
-5.8
--------------6.9
No significant outcome(14).
-5.9
Decrease in mortality rate(15).
-5.5
--------------Antivirals
-5.7
Shortens the time of recovery(16).
Early administration decreases the intensity of
-4.5
symptoms(17).
Reduces viral load and inhibits spike protein
-6.2
trimerization(18).
-5.0
Not effective
-4.8
Decreases viral load(19).
Macrolides
Shows antiviral and immunomodulatory ef-8.5
fects(20).

Calcium channel blocker
Ipratropium

-4.9

-6.4

----------------
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The RBD in SARS-CoV-2, forms two
additional bonds at N-terminal helix with
serine -19 and tyrosine-83 leading to change
in conformation of residues at the binding site.
The conformational changes in the residues
at the binding site were explained by docking
drugs at the selected residues on the binding
sitesof ACE-2 receptors in both SARS-CoV
and SARS-CoV-2.The difference in binding
when losartan an ACE-2 inhibitor is docked is
clearly visible as shown in Figure 2. In case
of the ACE-2 receptor in SARS-CoV crystal
structure (Fig-2A) losartan was found binding
to histidine 34, aspartic acid 38 and lysine 353.
The drug binds to the terminal hydrogens of
lysine 353. Whereas in case of ACE-2 receptor
in SARS-CoV-2 crystal structure (Fig-2B)was
found to bind with only lysine 353 but not to the
highlighted terminal hydrogens.
This difference in thebinding could be
attributed to the conformational changes
occurred at the binding sites on ACE-2 receptor.
The bond lengths of the interactions
between losartan and lysine 353 in Table-2
shows that losartan has a greater number of
interactions with lesser bond lengths in SARSCoV-2 when compared to SARS-CoV indicating
strong interactions. The docking score of
losartan at ACE-2 receptor of SARS-CoV-2 is
-5.9 and that of SARS CoV is -4.4, indicating its
greater binding affinitytowards ACE-2 receptors
in SARS-CoV-2.
Various drug moieties belonging to
antivirals, ACE-2 inhibitors, corticosteroids,
macrolides, and antibiotics were docked. The
obtained docking score was utilized to study
why certain drugs were ineffective and which
drugs might show some potency in the present
COVID-19 treatment scenario.The drugs that
were docked at the RBD binding site in ACE-2
receptors with the docking score and the clinical
outcomes from various studies conducted are
shown in Table 3.Most of the drug moieties
have shown a greater negative score when
docked at ACE-2 receptors in SARS-CoV-2
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when compared to that of SARS-CoV, indicating
higher binding affinity. All the drugs that have
shown a high binding affinity in case of SARSCoV-2were found to bind at lysine353 with
greater number of interactions. Levofloxacin
which forms only one interaction with lysine 353
was ineffective, whereas moxifloxacin forms
seven bonds was effective.
Drugs having a greater negative score than
-5.0 were found to be effective in SARS-CoV-2
by either reducing the viral load or by treating
the associated pneumonia or both. There are
a couple drugs which have a score less than
-5.0 but were found to decrease viral load and
intensity of symptoms associated with SARSCoV-2.Favipiravir and oseltamivir have scores
of -4.8 and -4.5 respectively when docked
at ACE-2 binding residues inSARS-CoV-2,
which are comparatively greater than -4.3 and
-3.9 in SARS-CoV respectively. Drugs such
as valsartan and ipratropium have shown a
greater negative score and stronger binding at
lysine 353 residue, yet no clinical data available
to corroborate their potential in COVID-19
treatment.
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Conclusion
The studies conducted on crystal structures of
ACE-2 bound spike RBDs of SARS-CoV and
SARS-CoV-2 using UCSF Chimera, pyMOL and
Autodock vina revealed the structural differences
in the binding spots and conformational changes
at the receptor binding sites between the two
viruses. The drugs that yielded a more negative
docking score, greater than -5.0were observed
to have potential in reducing viral load and
associated pneumonia. As pandemic disease
like COVID-19 strike the humanity, a preliminary
analysis with computational methods could help
in the design of new treatments or repurposing
of the current treatments.
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